Pathological Complete Response After Nivolumab Therapy Following Angiogenesis Inhibitors in a Patient with Metastatic Renal Cell Carcinoma

Overview

Journal IJU Case Rep

Date 2020 Nov 9

PMID 33163928

Citations 7

Authors

Hiroki Hagimoto

Soki Kashima

Kazuki Doi

Shintaro Nakayama

Takanori Sano

Satoshi Imai

Tomihiko Yasufuku

Mototsugu Muramaki

Yuji Yamada

Affiliations

Soon will be listed here.

Abstract

Introduction: Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.

Case Presentation: A 65-year-old man was diagnosed with left renal cell carcinoma of cT2aN0M1 with lung metastasis. The patient underwent nephrectomy and sequential therapy with interferon-α and angiogenesis inhibitors. Lung metastasis decreased by angiogenesis inhibitors, but new right adrenal gland metastasis appeared. Nivolumab as the fifth systemic therapy remarkably shrank the metastasis. After discontinuing nivolumab therapy, the metastasis continued to shrink. The patient underwent adrenalectomy, and pathological analysis revealed no remnant cancer cells in the specimen, confirming a pathological complete response. Twenty months postoperatively, he remains in good health without recurrence.

Conclusion: We report a rare case with renal cell carcinoma of a pathological complete response by nivolumab after angiogenesis inhibitors.

Citing Articles

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib.

Hayashida M, Miura Y, Yamaguchi T, Tanaka M, Yamanaka T, Takemura K IJU Case Rep. 2023; 6(6):419-423.

PMID: 37928303 PMC: 10622194. DOI: 10.1002/iju5.12638.

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma.

Studentova H, Spisarova M, Kopova A, Zemankova A, Melichar B, Student Jr V Cancers (Basel). 2023; 15(15).

PMID: 37568671 PMC: 10417043. DOI: 10.3390/cancers15153855.

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab.

Hayashida M, Miura Y, Noda T, Yamanaka T, Tanaka N, Yasuoka S IJU Case Rep. 2022; 5(4):268-272.

PMID: 35795114 PMC: 9249646. DOI: 10.1002/iju5.12452.

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.

Studentova H, Zemankova A, Spisarova M, Skanderova D, Tudos Z, Melichar B Medicina (Kaunas). 2022; 58(3).

PMID: 35334512 PMC: 8951627. DOI: 10.3390/medicina58030336.

Editorial Comment from Dr Kobayashi to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.

Kobayashi T IJU Case Rep. 2020; 3(6):292.

PMID: 33163930 PMC: 7609187. DOI: 10.1002/iju5.12225.

References

Shiraishi Y, Terakawa T, Jimbo N, Shigemura K, Hinata N, Fujisawa M . Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava. Int J Urol. 2018; 26(2):313-314. DOI: 10.1111/iju.13853. View

Stenzel P, Schindeldecker M, Tagscherer K, Foersch S, Herpel E, Hohenfellner M . Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Transl Oncol. 2019; 13(2):336-345. PMC: 7031108. DOI: 10.1016/j.tranon.2019.11.002. View

Ikarashi D, Kato Y, Katagiri H, Takahara T, Uesugi N, Shiomi E . Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma. Int J Urol. 2018; 25(6):630-632. DOI: 10.1111/iju.13590. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Bhat A, Nahar B, Venkatramani V, Banerjee I, Kryvenko O, Parekh D . Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy. Case Rep Urol. 2019; 2019:7102504. PMC: 6437729. DOI: 10.1155/2019/7102504. View

Rini B, Plimack E, Stus V, Gafanov R, Hawkins R, Nosov D . Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1116-1127. DOI: 10.1056/NEJMoa1816714. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A . Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019; 18(1):60. PMC: 6441150. DOI: 10.1186/s12943-019-0974-6. View

Wade L, Hilman S . One dose of immunotherapy leading to an exceptional and durable response in a patient with metastatic renal cell carcinoma. Oxf Med Case Reports. 2020; 2019(12):516-518. PMC: 6937447. DOI: 10.1093/omcr/omz128. View

10.

Hagimoto H, Kashima S, Doi K, Nakayama S, Sano T, Imai S . Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU Case Rep. 2020; 3(6):287-290. PMC: 7609183. DOI: 10.1002/iju5.12220. View

11.

Takagi T, Yoshida K, Kobayashi H, Kondo T, Iizuka J, Okumi M . Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2018; 48(9):860-863. DOI: 10.1093/jjco/hyy106. View

12.

Motzer R, Penkov K, Haanen J, Rini B, Albiges L, Campbell M . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380(12):1103-1115. PMC: 6716603. DOI: 10.1056/NEJMoa1816047. View

13.

Shirotake S, Kaneko G, Nagata K, Oyama M, Nishimoto K . Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report. Mol Clin Oncol. 2019; 10(2):244-248. PMC: 6327208. DOI: 10.3892/mco.2018.1779. View

14.

Labbate C, Hatogai K, Werntz R, Stadler W, Steinberg G, Eggener S . Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019; 7(1):66. PMC: 6413449. DOI: 10.1186/s40425-019-0546-8. View

15.

Shepherd A, Joshi R, Tan C, Cohen P, Brook N . Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma. ANZ J Surg. 2019; 90(7-8):1517-1519. DOI: 10.1111/ans.15608. View

16.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

17.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

18.

Giraldo N, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P . Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(15):4416-4428. DOI: 10.1158/1078-0432.CCR-16-2848. View

19.

Lyon T, Thompson R, Shah P, Lohse C, Boorjian S, Costello B . Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. J Urol. 2019; 203(2):275-282. DOI: 10.1097/JU.0000000000000488. View